Ilir Agalliu1, Susan Gapstur2, Zigui Chen3, Tao Wang1, Rebecca L Anderson2, Lauren Teras2, Aimée R Kreimer4, Richard B Hayes5, Neal D Freedman4, Robert D Burk6. 1. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York. 2. American Cancer Society, Atlanta, Georgia. 3. Department of Pediatrics (Genetics), Albert Einstein College of Medicine, Bronx, New York. 4. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 5. Department of Population Health and Environmental Medicine, New York University, New York. 6. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York3Department of Pediatrics (Genetics), Albert Einstein College of Medicine, Bronx, New York6Departments of Microbiology and Immunology and Obstetrics, Gyn.
Abstract
IMPORTANCE: Prospective studies are needed to examine the temporal relationship between oral human papillomavirus (HPV) detection and risk of head and neck squamous cell carcinoma (HNSCC). Moreover, the oral cavity contains a wide spectrum of α-, β-, and γ-HPV types, but their association with risk of HNSCC is unknown. OBJECTIVE: To prospectively examine associations between α-, β-, and γ-HPV detection in the oral cavity and incident HNSCC. DESIGN: A nested case-control study was carried out among 96 650 participants, cancer free at baseline, with available mouthwash samples in 2 prospective cohort studies: (1) the American Cancer Society Cancer Prevention Study II Nutrition Cohort and (2) the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Incident cases of HNSCC (n = 132) were identified during an average 3.9 years of follow-up in both cohorts. Three controls per case (n = 396) were selected through incidence density sampling and matched on age, sex, race/ethnicity, and time since mouthwash collection. METHODS: Through a next-generation sequencing assay, DNA from α-, β-, and γ-HPV types were detected. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% CIs, adjusting for smoking history, alcohol consumption, and detection of HPV-16 for β- and γ-HPVs. MAIN OUTCOMES AND MEASURES: Incident HNSCC, which includes cancers of the oropharynx, oral cavity, and larynx. RESULTS: A total of 132 participants developed HNSCC during the follow-up period (103 men and 29 women; average age at baseline, 66.5 years). Oral HPV-16 detection was associated with incident HNSCC (OR, 7.1; 95% CI, 2.2-22.6), with positive association for oropharyngeal SCC (OR, 22.4; 95% CI, 1.8-276.7), but not for oral cavity (OR, 4.5; 95% CI, 0.6-34.7) or laryngeal SCCs (OR, 0.11; 95% CI, 0.01-834.80). Detection of β1-HPV-5 and β2-HPV-38 types, as well as γ-11 and γ-12 species, had ORs for HNSCC that ranged from 2.64 to 5.45 (P < .01 for all comparisons). Detection of β1-HPV-5 type was associated with oropharyngeal (OR, 7.42; 95% CI, 0.98-56.82; P = .054), oral cavity (OR, 5.34; 95% CI, 1.51-18.80; P = .01), and laryngeal SCCs (OR, 2.71; 95% CI, 1.00-7.43; P = .05), whereas γ11- and γ12-HPV species were associated with both oral cavity (OR, 7.47; 95% CI, 1.21-46.17; P = .03; and OR, 6.71; 95% CI, 1.47-30.75; P = .01, respectively) and laryngeal SCCs (OR, 7.49; 95% CI, 1.10-51.04; P = .04 and OR, 5.31; 95% CI, 1.13-24.95; P = .03, respectively). CONCLUSIONS AND RELEVANCE: This study demonstrates that HPV-16 detection precedes the incidence of oropharyngeal SCC. Associations of other HPVs, including γ11- and γ12-HPV species and β1-HPV-5 type suggest a broader role for HPVs in HNSCC etiology.
IMPORTANCE: Prospective studies are needed to examine the temporal relationship between oral human papillomavirus (HPV) detection and risk of head and neck squamous cell carcinoma (HNSCC). Moreover, the oral cavity contains a wide spectrum of α-, β-, and γ-HPV types, but their association with risk of HNSCC is unknown. OBJECTIVE: To prospectively examine associations between α-, β-, and γ-HPV detection in the oral cavity and incident HNSCC. DESIGN: A nested case-control study was carried out among 96 650 participants, cancer free at baseline, with available mouthwash samples in 2 prospective cohort studies: (1) the American Cancer Society Cancer Prevention Study II Nutrition Cohort and (2) the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Incident cases of HNSCC (n = 132) were identified during an average 3.9 years of follow-up in both cohorts. Three controls per case (n = 396) were selected through incidence density sampling and matched on age, sex, race/ethnicity, and time since mouthwash collection. METHODS: Through a next-generation sequencing assay, DNA from α-, β-, and γ-HPV types were detected. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% CIs, adjusting for smoking history, alcohol consumption, and detection of HPV-16 for β- and γ-HPVs. MAIN OUTCOMES AND MEASURES: Incident HNSCC, which includes cancers of the oropharynx, oral cavity, and larynx. RESULTS: A total of 132 participants developed HNSCC during the follow-up period (103 men and 29 women; average age at baseline, 66.5 years). Oral HPV-16 detection was associated with incident HNSCC (OR, 7.1; 95% CI, 2.2-22.6), with positive association for oropharyngeal SCC (OR, 22.4; 95% CI, 1.8-276.7), but not for oral cavity (OR, 4.5; 95% CI, 0.6-34.7) or laryngeal SCCs (OR, 0.11; 95% CI, 0.01-834.80). Detection of β1-HPV-5 and β2-HPV-38 types, as well as γ-11 and γ-12 species, had ORs for HNSCC that ranged from 2.64 to 5.45 (P < .01 for all comparisons). Detection of β1-HPV-5 type was associated with oropharyngeal (OR, 7.42; 95% CI, 0.98-56.82; P = .054), oral cavity (OR, 5.34; 95% CI, 1.51-18.80; P = .01), and laryngeal SCCs (OR, 2.71; 95% CI, 1.00-7.43; P = .05), whereas γ11- and γ12-HPV species were associated with both oral cavity (OR, 7.47; 95% CI, 1.21-46.17; P = .03; and OR, 6.71; 95% CI, 1.47-30.75; P = .01, respectively) and laryngeal SCCs (OR, 7.49; 95% CI, 1.10-51.04; P = .04 and OR, 5.31; 95% CI, 1.13-24.95; P = .03, respectively). CONCLUSIONS AND RELEVANCE: This study demonstrates that HPV-16 detection precedes the incidence of oropharyngeal SCC. Associations of other HPVs, including γ11- and γ12-HPV species and β1-HPV-5 type suggest a broader role for HPVs in HNSCC etiology.
Authors: Eugenia E Calle; Carmen Rodriguez; Eric J Jacobs; M Lyn Almon; Ann Chao; Marjorie L McCullough; Heather S Feigelson; Michael J Thun Journal: Cancer Date: 2002-01-15 Impact factor: 6.860
Authors: M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: Richard B Hayes; Alice Sigurdson; Lee Moore; Ulrike Peters; Wen-Yi Huang; Paul Pinsky; Douglas Reding; Edward P Gelmann; Nat Rothman; Ruth M Pfeiffer; Robert N Hoover; Christine D Berg Journal: Mutat Res Date: 2005-07-27 Impact factor: 2.433
Authors: Philip E Castle; Mark Schiffman; Patti E Gravitt; Hortense Kendall; Stacy Fishman; Huali Dong; Allan Hildesheim; Rolando Herrero; M Concepcion Bratti; Mark E Sherman; Attila Lorincz; John E Schussler; Robert D Burk Journal: J Med Virol Date: 2002-11 Impact factor: 2.327
Authors: Rolando Herrero; Xavier Castellsagué; Michael Pawlita; Jolanta Lissowska; Frank Kee; Prabda Balaram; Thangarajan Rajkumar; Hema Sridhar; Barbara Rose; Javier Pintos; Leticia Fernández; Ali Idris; María José Sánchez; Adoración Nieto; Renato Talamini; Alessandra Tavani; F Xavier Bosch; Ulrich Reidel; Peter J F Snijders; Chris J L M Meijer; Raphael Viscidi; Nubia Muñoz; Silvia Franceschi Journal: J Natl Cancer Inst Date: 2003-12-03 Impact factor: 13.506
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Javier Pintos; Martin J Black; Nader Sadeghi; Parviz Ghadirian; Anthony G Zeitouni; Raphael P Viscidi; Rolando Herrero; François Coutlée; Eduardo L Franco Journal: Oral Oncol Date: 2007-04-27 Impact factor: 5.337
Authors: Elaine M Smith; Justine M Ritchie; Kurt F Summersgill; Henry T Hoffman; Dong Hong Wang; Thomas H Haugen; Lubomir P Turek Journal: J Natl Cancer Inst Date: 2004-03-17 Impact factor: 13.506
Authors: Gypsyamber D'Souza; Gwendolyn Clemens; Tanya Troy; Rachel G Castillo; Linda Struijk; Tim Waterboer; Noemi Bender; Phillip M Pierorazio; Simon R Best; Howard Strickler; Dorothy J Wiley; Robert I Haddad; Marshall Posner; Carole Fakhry Journal: Cancer Prev Res (Phila) Date: 2019-08-16
Authors: Daniel C Beachler; Krystle A Lang Kuhs; Linda Struijk; John Schussler; Rolando Herrero; Carolina Porras; Allan Hildesheim; Bernal Cortes; Joshua Sampson; Wim Quint; Paula Gonzalez; Aimée R Kreimer Journal: Sex Transm Dis Date: 2017-07 Impact factor: 2.830
Authors: Helen C Stankiewicz Karita; Amalia Magaret; Meei-Li Huang; Keith R Jerome; Quinne Feng; Anna Wald Journal: Sex Transm Dis Date: 2020-02 Impact factor: 2.830
Authors: Laura Sichero; Mariam El-Zein; Emily M Nunes; Silvaneide Ferreira; Eduardo L Franco; Luisa L Villa Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-04-04 Impact factor: 4.254
Authors: Yuehan Zhang; Tim Waterboer; Robert I Haddad; Brett A Miles; Alicia Wentz; Neil D Gross; Carole Fakhry; Harry Quon; Jochen H Lorch; Christine G Gourin; Daniel Clayburgh; Krzysztof J Misiukiewicz; Jeremy D Richmon; Peter E Andersen; Marshall R Posner; Gypsyamber D'Souza Journal: Oral Oncol Date: 2017-02-15 Impact factor: 5.337
Authors: Ilir Agalliu; Zigui Chen; Tao Wang; Richard B Hayes; Neal D Freedman; Susan M Gapstur; Robert D Burk Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-08-07 Impact factor: 4.254